MX2017016772A - Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo. - Google Patents
Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo.Info
- Publication number
- MX2017016772A MX2017016772A MX2017016772A MX2017016772A MX2017016772A MX 2017016772 A MX2017016772 A MX 2017016772A MX 2017016772 A MX2017016772 A MX 2017016772A MX 2017016772 A MX2017016772 A MX 2017016772A MX 2017016772 A MX2017016772 A MX 2017016772A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolo
- producing
- pyrimidine derivative
- diazaspiro
- octan
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title abstract 3
- 102000015617 Janus Kinases Human genes 0.000 abstract 2
- 108010024121 Janus Kinases Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
La presente invencion proporciona un metodo para reducir un derivado de 7H-pirrolo[2,3-d]pirimidina que es util como un inhibidor de la quinasa janus (JAK); un intermediario del derivado 7H-pirrolo[2,3-d]pirimidina; y un metodo para producir el intermediario; la presente invencion proporciona un metodo para producir 3-[(3S,4R)-3- metil-6-(7H-pirrolo[2,3-d]pirimidin-4- il)-1,6-diazaspiro[3.4]octan-1-il]-3- oxopropanenitrilo, el cual utiliza una sal de un acido organico y bencilo de acido (3S,4R)- 3-metil-1,6-diazaspiro[3.4]octano-1-carboxilico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015136196 | 2015-07-07 | ||
| PCT/JP2016/070046 WO2017006968A1 (ja) | 2015-07-07 | 2016-07-06 | ７Ｈ－ピロロ［２，３－ｄ］ピリミジン誘導体の製造方法及びその中間体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017016772A true MX2017016772A (es) | 2018-05-14 |
Family
ID=57685105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016772A MX2017016772A (es) | 2015-07-07 | 2016-07-06 | Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10822354B2 (es) |
| EP (1) | EP3321271B1 (es) |
| JP (1) | JP6871856B2 (es) |
| KR (1) | KR20180025940A (es) |
| CN (1) | CN107709337B (es) |
| AU (1) | AU2016289061B2 (es) |
| BR (1) | BR112017026173A2 (es) |
| CA (1) | CA2991020A1 (es) |
| HK (1) | HK1251223A1 (es) |
| IL (1) | IL255775B (es) |
| MX (1) | MX2017016772A (es) |
| RU (1) | RU2755618C2 (es) |
| TW (1) | TWI729990B (es) |
| WO (1) | WO2017006968A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1251223A1 (en) | 2015-07-07 | 2019-01-25 | Japan Tobacco, Inc. | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
| JP2020502224A (ja) * | 2016-12-21 | 2020-01-23 | 日本たばこ産業株式会社 | ヤヌスキナーゼ阻害剤の結晶形 |
| CN110300756B (zh) | 2016-12-21 | 2024-01-02 | 日本烟草产业株式会社 | 7H-吡咯并[2,3-d]嘧啶衍生物的制备方法及其合成中间体 |
| BR112019012267A2 (pt) | 2016-12-21 | 2019-12-03 | Japan Tobacco Inc | processo para a preparação do derivado de 7h-pirrolo [2,3-d]pirimidina e cocristais do mesmo |
| KR20190105417A (ko) | 2018-03-05 | 2019-09-17 | 현대자동차주식회사 | 브리더 호스 미체결 진단 방법 |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| CN114173788A (zh) * | 2019-08-07 | 2022-03-11 | 乐敦制药株式会社 | 泪液分泌促进用眼科组合物 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021132598A1 (ja) | 2019-12-27 | 2021-07-01 | ロート製薬株式会社 | 水性組成物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN111606929B (zh) * | 2020-06-30 | 2023-07-07 | 中瀚(齐河县)生物医药科技有限公司 | 德高替尼的制备方法 |
| CN111574540B (zh) * | 2020-06-30 | 2023-08-29 | 云南华派医药科技有限公司 | 一种德高替尼的制备方法 |
| JPWO2022025279A1 (es) | 2020-07-30 | 2022-02-03 | ||
| EP4176881A4 (en) | 2020-07-30 | 2024-07-31 | Rohto Pharmaceutical Co., Ltd. | Aqueous composition |
| AU2024229918A1 (en) | 2023-02-28 | 2025-09-18 | Assia Chemical Industries Ltd. | Solid state forms of delgocitinib and process thereof |
| WO2024225445A1 (en) | 2023-04-27 | 2024-10-31 | Japan Tobacco Inc. | Crystalline form of delgocitinib |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7230119B2 (en) | 2004-08-25 | 2007-06-12 | Biocryst Pharmaceuticals, Inc. | Process for the preparation of substituted pyrrolidine derivatives and intermediates |
| DK2078022T3 (da) | 2006-09-22 | 2012-02-13 | Janssen Pharmaceutica Nv | Spirobenzazepiner anvendt som vasopressinantagonister |
| ES2335380B1 (es) * | 2008-09-24 | 2011-03-22 | Consejo Superior De Investigaciones Cientificas (Csic) | Nuevos aminoacidos cuaternarios derivados de azepanos y sus aplicaciones. |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| PH12013501437A1 (en) * | 2011-01-19 | 2013-09-16 | Galapagos Nv | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases |
| CN103570601B (zh) | 2012-07-20 | 2016-03-30 | 重庆博腾制药科技股份有限公司 | 一种光学活性药物中间体的制备方法 |
| DK2964616T3 (en) | 2013-03-05 | 2017-08-28 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| HK1251223A1 (en) | 2015-07-07 | 2019-01-25 | Japan Tobacco, Inc. | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
| CN110300756B (zh) | 2016-12-21 | 2024-01-02 | 日本烟草产业株式会社 | 7H-吡咯并[2,3-d]嘧啶衍生物的制备方法及其合成中间体 |
-
2016
- 2016-07-06 HK HK18110560.9A patent/HK1251223A1/en unknown
- 2016-07-06 JP JP2017527480A patent/JP6871856B2/ja active Active
- 2016-07-06 US US15/741,926 patent/US10822354B2/en active Active
- 2016-07-06 EP EP16821437.7A patent/EP3321271B1/en active Active
- 2016-07-06 AU AU2016289061A patent/AU2016289061B2/en not_active Ceased
- 2016-07-06 MX MX2017016772A patent/MX2017016772A/es unknown
- 2016-07-06 KR KR1020187003308A patent/KR20180025940A/ko not_active Ceased
- 2016-07-06 CN CN201680040056.7A patent/CN107709337B/zh active Active
- 2016-07-06 CA CA2991020A patent/CA2991020A1/en not_active Abandoned
- 2016-07-06 TW TW105121354A patent/TWI729990B/zh not_active IP Right Cessation
- 2016-07-06 BR BR112017026173-1A patent/BR112017026173A2/pt not_active IP Right Cessation
- 2016-07-06 WO PCT/JP2016/070046 patent/WO2017006968A1/ja not_active Ceased
- 2016-07-06 RU RU2018104347A patent/RU2755618C2/ru active
-
2017
- 2017-11-20 IL IL255775A patent/IL255775B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US10822354B2 (en) | 2020-11-03 |
| JPWO2017006968A1 (ja) | 2018-04-19 |
| TWI729990B (zh) | 2021-06-11 |
| EP3321271A4 (en) | 2020-12-16 |
| WO2017006968A1 (ja) | 2017-01-12 |
| HK1251223A1 (en) | 2019-01-25 |
| CA2991020A1 (en) | 2017-01-12 |
| JP6871856B2 (ja) | 2021-05-19 |
| AU2016289061A1 (en) | 2017-12-21 |
| CN107709337B (zh) | 2021-11-16 |
| CN107709337A (zh) | 2018-02-16 |
| KR20180025940A (ko) | 2018-03-09 |
| AU2016289061B2 (en) | 2020-07-09 |
| BR112017026173A2 (pt) | 2018-08-14 |
| IL255775B (en) | 2021-03-25 |
| RU2018104347A3 (es) | 2019-12-23 |
| RU2755618C2 (ru) | 2021-09-17 |
| US20190062346A1 (en) | 2019-02-28 |
| EP3321271A1 (en) | 2018-05-16 |
| TW201708231A (zh) | 2017-03-01 |
| RU2018104347A (ru) | 2019-08-08 |
| EP3321271B1 (en) | 2024-05-29 |
| IL255775A (en) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017016772A (es) | Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo. | |
| MX2024005335A (es) | Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos. | |
| CL2019000942A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| PH12020500201A1 (en) | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors | |
| ZA201800771B (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| WO2016063294A3 (en) | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| EA201591255A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) | |
| MA37316A1 (fr) | Dérivés de 2-amino, 6-phenyl à substitution pyrido [2, 3 - d] pyrimidine utilisés en tant qu'inhibiteurs de la raf kinase | |
| MX2019007452A (es) | Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos. | |
| MX2017015837A (es) | Procesos e intermediarios para la preparacion de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-piraz ol-1-il]azetidin-3-il}acetonitrilo. | |
| PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
| IL273396B (en) | 4-[[(7-aminopyrazolo[5,1-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as cdk inhibitors | |
| MX386181B (es) | Formas cristalinas de un inhibidor de quinasa janus | |
| WO2018218197A3 (en) | ATR KINASE INHIBITORS BASED ON TETRAHYDROPYRIDO [4,3-D] PYRIMIDINE | |
| AU2017319080A1 (en) | Pyrazolo[1,5-a]pyrimidine compound | |
| MA46690A (fr) | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 | |
| PH12019500478A1 (en) | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof | |
| EP4257205A3 (en) | Treatment of hand eczema | |
| SG10201806450SA (en) | PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | |
| MX2017003415A (es) | Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace. | |
| HK40065699B (zh) | 经取代的吡唑并[1 ,5-a]吡啶化合物作为ret激酶抑制剂 | |
| HK40065699A (zh) | 经取代的吡唑并[1 ,5-a]吡啶化合物作为ret激酶抑制剂 | |
| PL3621966T3 (pl) | Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK |